Search Within

Molecular Pharmacology and Chemistry Program Faculty

Formats
  1. Journal Article (4981)
  2. Meeting Abstract (2012)
  3. Book Section (218)
  4. Conference Paper (122)
  5. Review (81)
  6. Editorial (50)
  7. Book Whole (30)
  8. Research Letter (15)
  9. Correspondence (8)
  10. Miscellaneous (6)
  11. Guidelines (2)
Groups
  1. Sloan Kettering Institute Faculty (7525)
  2. GSK Faculty (4733)
  3. Department of Medicine (2732)
  4. Surgery (2099)
  5. Center for Hematologic Malignancies (1836)
  6. Radiology, Department of (1826)

More Groups

People
  1. Murray Brennan (1060)
  2. Steven Larson (962)
  3. Peter Scardino (672)
  4. Michel Sadelain (586)
  5. Samuel Danishefsky (539)
  6. David Scheinberg (502)

More People

Years
  1. 2025 (67)
  2. 2024 (98)
  3. 2023 (122)
  4. 2022 (151)
  5. 2021 (155)
  6. 2020 (162)

More Years

Publications
  1. Blood (384)
  2. Journal of Nuclear Medicine (383)
  3. Cancer Research (340)
  4. Journal of Clinical Oncology (316)
  5. Annals of Surgical Oncology (181)
  6. International Journal of Radiation Oncology, Biology, Physics (176)

More Publications

Publishers
  1. American Association for Cancer Research (713)
  2. Elsevier Inc. (674)
  3. Nature Publishing Group (493)
  4. Springer (468)
  5. American Chemical Society (444)
  6. Elsevier Science, Inc. (406)

More Publishers

Results (7525)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Genetic ablation of adhesion ligands effectively averts rejection of allogeneic immune cells
    Meeting Abstract

    Hammer, Q.; Perica, K.; Mbofung, R. M.; Van Ooijen, H.; Goodridge, J. P.; Valamehr, B.; Önfelt, B.; Sadelain, M.; Malmberg, K. J.
    European Journal of Immunology (2022)

    Fulltext@MSK | Save
  • Establishment of efficacy of DOTA-based pretargeted radioimmunotherapy with a bivalent radiohapten for enhanced therapeutic indices
    Meeting Abstract

    Vaughn, B.; Veach, D.; Vargas, D. B.; Seo, S.; Punzalan, B.; Zanzonico, P.; Xu, H.; Guo, H. F.; Yang, G.; Ouerfelli, O.; more...
    Journal of Nuclear Medicine (2022)

    Fulltext@MSK | Save
  • Ultrasmall folate receptor alpha targeted enzymatically cleavable silica nanoparticle drug conjugates augment penetration and therapeutic efficacy in models of cancer
    Journal Article

    Wu, F.; Chen, P. M.; Gardinier, T. C.; Turker, M. Z.; Venkatesan, A. M.; Patel, V.; Khor, T.; Bradbury, M. S.; Wiesner, U. B.; Adams, G. P.; more...
    ACS Nano (2022)

    Fulltext@MSK | Save
  • Increased tumor glycolysis is associated with decreased immune infiltration across human solid tumors
    Journal Article

    Cohen, I. J.; Pareja, F.; Socci, N. D.; Shen, R.; Doane, A. S.; Schwartz, J.; Khanin, R.; Morris, E. A.; Sutton, E. J.; Blasberg, R. G.
    Frontiers in Immunology (2022)

    Fulltext@MSK | Save
  • Phase 1 study of intraventricular (131)I-omburtamab targeting B7H3 (CD276)-expressing CNS malignancies
    Meeting Abstract

    Modak, S.; Pandit Taskar, N.; Kushner, B.; Zanzonico, P.; Humm, J.; Donzelli, M.; Lewis, J.; Lyashchenko, S.; Chu, B.; Larson, S.; more...
    Pediatric Blood and Cancer (2022)

    Fulltext@MSK | Save
  • Clinicopathologic characterization of ERK2 E322K mutation in solid tumors: Implications for treatment and drug development
    Meeting Abstract

    Liu, D.; Murciano-Goroff, Y. R.; Jee, J.; Arcila, M. E.; Buonocore, D. J.; Gao, J.; Chakravarty, D.; Schram, A. M.; Callahan, M. K.; Friedman, C. F.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • STARLITE 2: Phase 2 study of nivolumab plus (177)Lutetium-labeled anti-carbonic anhydrase IX (CAIX) monoclonal antibody girentuximab ((177)Lu-girentuximab) in patients (pts) with advanced clear cell renal cell carcinoma (ccRCC)
    Meeting Abstract

    Feldman, D. R.; Motzer, R. J.; Knezevic, A.; Lee, C. H.; Voss, M. H.; Lyashchenko, S. K.; Park, H.; Larson, S. M.; Pandit-Taskar, N.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • The bi-steric mTORC1-selective inhibitor RMC-5552 in tumors with activation of mTOR signaling: Preclinical activity in combination with RAS(ON) inhibitors in RAS-addicted tumors, and initial clinical findings from a single agent phase 1/1b study
    Meeting Abstract

    Burris, H. A. 3rd; Ulahannan, S. V.; Haura, E. B.; Ou, S. H. I.; Capasso, A.; Munster, P. N.; Kitai, H.; Wang, Z.; Hayes, J.; Tao, L.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Phase 2 of trametinib plus radioiodine in RAS-mutant and wild-type, radioiodine-refractory thyroid cancer (ETCTN9446)
    Meeting Abstract

    Burman, B.; Tuttle, R. M.; Grewal, R. K.; Sherman, E. J.; Baxi, S. S.; Boucai, L.; Sabra, M.; Fish, S.; Pentlow, K. S.; Haque, S.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • A randomized trial on pelvic lymph node dissection versus no lymph node dissection at radical prostatectomy: Report of a trial in progress
    Meeting Abstract

    Benfante, N.; Carroll, E.; Carruthers, J.; Donahue, T. F.; Eastham, J. A.; Ehdaie, B.; Goh, A. C.; Laudone, V. P.; Pietzak, E. J.; Smith, R.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save